

December 7, 2018

The Manager- Listing  
**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai - 400051

Dear Sir(s),

**Sub: Intimation about Distribution Agreement between AstraZeneca Pharma India Limited (“Company”) and Abbott Healthcare Private Limited (“Abbott”) for innovative type 2 diabetes medicine, Dapagliflozin.**

We wish to inform that the Company and Abbott have today entered into a Distribution Agreement for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is Company’s leading diabetes medicine.

Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name **GLEDEPA**. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name **GLEDEPA MET**.

The Company will continue to promote and distribute dapagliflozin under the brand name **Forxiga** and combination of dapagliflozin with metformin under the brand name **Xigduo**.

We request you to kindly take this intimation on records.

Thanking you,

For AstraZeneca Pharma India Limited

  
**Pratap Rudra**

**Company Secretary & Legal Counsel**

